List of Calithera Biosciences patents

Patents where

Current Assignee

Name

Calithera Biosciences

Name	Description	Patent Applicant	Current Assignee	Patent Jurisdiction	Patent Number	Date of Patent
‌ US Patent 10287303 Compositions and methods for inhibiting arginase activity	Patent 10287303 was granted and assigned to Calithera Biosciences on May, 2019 by the United States Patent and Trademark Office.	Calithera Biosciences	Calithera Biosciences	United States Patent and Trademark Office	10287303	May 14, 2019
‌ US Patent 11352355 Solid state forms of fused heteroaromatic pyrrolidinones	Patent 11352355 was granted and assigned to Calithera Biosciences on June, 2022 by the United States Patent and Trademark Office.	Calithera Biosciences	Calithera Biosciences	United States Patent and Trademark Office	11352355	June 7, 2022
‌ US Patent 11370754 Method of preparing (3R,4S)-3-acetamido-4-allyl-n-(tert-butyl)pyrrolidine-3-carboxamide	Patent 11370754 was granted and assigned to Calithera Biosciences on June, 2022 by the United States Patent and Trademark Office.	Calithera Biosciences	Calithera Biosciences	United States Patent and Trademark Office	11370754	June 28, 2022
‌ US Patent 10143699 Compositions and methods for inhibiting arginase activity	Patent 10143699 was granted and assigned to Calithera Biosciences on December, 2018 by the United States Patent and Trademark Office.	Calithera Biosciences	Calithera Biosciences	United States Patent and Trademark Office	10143699	December 4, 2018
‌ US Patent 11021495 Compositions and methods for inhibiting arginase activity	Patent 11021495 was granted and assigned to Calithera Biosciences on June, 2021 by the United States Patent and Trademark Office.	Calithera Biosciences	Calithera Biosciences	United States Patent and Trademark Office	11021495	June 1, 2021
‌ US Patent 10494339 Method of preparing (3R,4S)-3-acetamido-4-allyl-N-(tert-butyl)pyrrolidine-3-carboxamide	Patent 10494339 was granted and assigned to Calithera Biosciences on December, 2019 by the United States Patent and Trademark Office.	Calithera Biosciences	Calithera Biosciences	United States Patent and Trademark Office	10494339	December 3, 2019
‌ US Patent 11291674 Arginase inhibitor combination therapies		Calithera Biosciences	Calithera Biosciences	United States Patent and Trademark Office	11291674	April 5, 2022
‌ US Patent 10940148 Combination therapy with glutaminase inhibitors and immuno-oncology agents	Patent 10940148 was granted and assigned to Calithera Biosciences on March, 2021 by the United States Patent and Trademark Office.	Calithera Biosciences	Calithera Biosciences	United States Patent and Trademark Office	10940148	March 9, 2021
‌ US Patent 10258619 Combination therapy with glutaminase inhibitors and immuno-oncology agents	Patent 10258619 was granted and assigned to Calithera Biosciences on April, 2019 by the United States Patent and Trademark Office.	Calithera Biosciences	Calithera Biosciences	United States Patent and Trademark Office	10258619	April 16, 2019
‌ US Patent 10316030 Crystal forms of glutaminase inhibitors	Patent 10316030 was granted and assigned to Calithera Biosciences on June, 2019 by the United States Patent and Trademark Office.	Calithera Biosciences	Calithera Biosciences	United States Patent and Trademark Office	10316030	June 11, 2019
‌ US Patent 9687485 Combination therapy with glutaminase inhibitors	Patent 9687485 was granted and assigned to Calithera Biosciences on June, 2017 by the United States Patent and Trademark Office.	Calithera Biosciences	Calithera Biosciences	United States Patent and Trademark Office	9687485	June 27, 2017
‌ US Patent 10441587 Treatment of lung cancer with inhibitors of glutaminase	Patent 10441587 was granted and assigned to Calithera Biosciences on October, 2019 by the United States Patent and Trademark Office.	Calithera Biosciences	Calithera Biosciences	United States Patent and Trademark Office	10441587	October 15, 2019
‌ US Patent 9938267 Heterocyclic inhibitors of glutaminase	Patent 9938267 was granted and assigned to Calithera Biosciences on April, 2018 by the United States Patent and Trademark Office.	Calithera Biosciences	Calithera Biosciences	United States Patent and Trademark Office	9938267	April 10, 2018
‌ US Patent 10278968 Combination therapy with glutaminase inhibitors	Patent 10278968 was granted and assigned to Calithera Biosciences on May, 2019 by the United States Patent and Trademark Office.	Calithera Biosciences	Calithera Biosciences	United States Patent and Trademark Office	10278968	May 7, 2019
‌ US Patent 10793535 Heterocyclic glutaminase inhibitors		Calithera Biosciences	Calithera Biosciences	United States Patent and Trademark Office	10793535	October 6, 2020
‌ US Patent 11034715 Ectonucleotidase inhibitors and methods of use thereof	Patent 11034715 was granted and assigned to Calithera Biosciences on June, 2021 by the United States Patent and Trademark Office.	Calithera Biosciences	Calithera Biosciences	United States Patent and Trademark Office	11034715	June 15, 2021
‌ US Patent 10676472 Crystal forms of glutaminase inhibitors		Calithera Biosciences	Calithera Biosciences	United States Patent and Trademark Office	10676472	June 9, 2020
‌ US Patent 10906872 Method of preparing (3R,4S)-3-acetamido-4-allyl-n-(tert-butyl)pyrrolidine-3-carboxamide	Patent 10906872 was granted and assigned to Calithera Biosciences on February, 2021 by the United States Patent and Trademark Office.	Calithera Biosciences	Calithera Biosciences	United States Patent and Trademark Office	10906872	February 2, 2021
‌ US Patent 11174261 Ectonucleotidase inhibitors and methods of use thereof	Patent 11174261 was granted and assigned to Calithera Biosciences on November, 2021 by the United States Patent and Trademark Office.	Calithera Biosciences	Calithera Biosciences	United States Patent and Trademark Office	11174261	November 16, 2021
‌ US Patent 10905701 Compositions and methods for inhibiting arginase activity	Patent 10905701 was granted and assigned to Calithera Biosciences on February, 2021 by the United States Patent and Trademark Office.	Calithera Biosciences	Calithera Biosciences	United States Patent and Trademark Office	10905701	February 2, 2021
‌ US Patent 10195197 Combination therapy with glutaminase inhibitors	Patent 10195197 was granted and assigned to Calithera Biosciences on February, 2019 by the United States Patent and Trademark Office.	Calithera Biosciences	Calithera Biosciences	United States Patent and Trademark Office	10195197	February 5, 2019
‌ US Patent 10844080 Compositions and methods for inhibiting arginase activity	Patent 10844080 was granted and assigned to Calithera Biosciences on November, 2020 by the United States Patent and Trademark Office.	Calithera Biosciences	Calithera Biosciences	United States Patent and Trademark Office	10844080	November 24, 2020
‌ US Patent 11078228 Ectonucleotidase inhibitors and methods of use thereof	Patent 11078228 was granted and assigned to Calithera Biosciences on August, 2021 by the United States Patent and Trademark Office.	Calithera Biosciences	Calithera Biosciences	United States Patent and Trademark Office	11078228	August 3, 2021
‌ US Patent 8865718 Heterocyclic inhibitors of glutaminase	Patent 8865718 was granted and assigned to Calithera Biosciences on October, 2014 by the United States Patent and Trademark Office.	Calithera Biosciences	Calithera Biosciences	United States Patent and Trademark Office	8865718	October 21, 2014
‌ US Patent 10851118 Compositions and methods for inhibiting arginase activity	Patent 10851118 was granted and assigned to Calithera Biosciences on December, 2020 by the United States Patent and Trademark Office.	Calithera Biosciences	Calithera Biosciences	United States Patent and Trademark Office	10851118	December 1, 2020

Results per page:

30 results

0 selected

30 results

0 selected